目的了解乙型肝炎与肝硬化患者表面抗原(HBsAg)与e抗原(HBeAg)定量变化规律,探讨分层次联合抗病毒治疗并争取满意效果的可行性。方法采用荧光磁微粒酶免法检测710例HBV相关肝病患者HBsAg和HBeAg,用SPSS19.0软件包进行统计学处理。结果 HBsAg<0.2 IU/mL61例,占8.5%;HBsAg>0.2 IU/mL~<100 IU/mL为低水平HBsAg组,55例,占7.7%;HBsAg>100 IU/mL~<1000 IU/mL为中等水平HBsAg组,142例,占20%;HBsAg 1000~5000 IU/mL为高水平HBsAg组,211例,占29.7%;HBsAg>5000 IU/mL为超高水平HBsAg组,241例,占33.9%;各型肝炎随年龄增大,HBsAg定量值逐步下降,转阴高峰集中在46岁左右;HBeAg阴性组(<1.0CI)453例,占63.8%;低水平HBeAg阳性组(>1.0CI~<10 CI)96例,占13.5%;中等量水平HBeAg阳性组(>10 CI~<100 CI)55例,占7.7%;高水平HBeAg阳性组(>100 CI~<500 CI)23例,占3.2%;超高水平HBeAg阳性组(>500 CI)83例,占11.6%;从慢性HBV携带者,慢性乙型肝炎,代偿期肝硬化到失代偿期肝硬化,年龄逐步增大,HBsAg和HBeAg定量秩均值逐步下降,卡方检验有显著性差异。结论 HBsAg和HBeAg定量随年龄增加与病情发展逐步下降,根据HBsAg,HBeAg和HBV DNA定量进行分层次联合抗病毒治疗可争取较满意效果。 Objective To investigate the quantitative changes of surface antigen (HBsAg) and e antigen (HBeAg) in patients with hepatitis B and cirrhosis, and to explore the feasibility of stratified combination of antiviral therapy and to obtain satisfactory results. Methods HBsAg and HBeAg in 710 cases of HBV-related liver disease were detected by fluorescent magnetic particle enzyme immunoassay and analyzed by SPSS19.0 software package. Results HBsAg was less than 0.2 IU / mL in 61 patients (8.5%). HBsAg was more than 0.2 IU / mL to less than 100 IU / mL in 55 patients (7.7%) and HBsAg was less than 100 IU / mL 142 cases accounted for 20%; HBsAg 1000-5000 IU / mL was high level HBsAg group, 211 cases (29.7%); HBsAg> 5000 IU / mL was super high level HBsAg group, 241 cases 33.9%. With the increase of age, the quantitative value of HBsAg gradually decreased and the peak of negative conversion was about 46 years old. The number of HBeAg negative group (<1.0CI) was 453 cases (63.8%), and the low level HBeAg positive group (> 1.0CI (CI) and CI (<10 CI) in 96 cases, accounting for 13.5%; moderate level of HBeAg positive group (> 10 CI ~ <100 CI) 55 cases, accounting for 7.7%; high level HBeAg positive group , Accounting for 3.2%; ultra-high level HBeAg-positive group (> 500 CI) 83 cases, accounting for 11.6%; from chronic HBV carriers, chronic hepatitis B, decompensated cirrhosis to decompensated cirrhosis, Large, HBsAg and HBeAg quantitative mean value of the gradual decline in the chi-square test were significantly different. Conclusion The quantification of HBsAg and HBeAg gradually decreases with the increase of age and progression of disease. Satisfactory results can be obtained according to the combination of HBsAg, HBeAg and HBV DNA quantitatively in combination with antiviral therapy.